Kyntra Bio, Inc. KYNB
1.56 USD -0.24 (-13.33%)
Regular-session close
1.56 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
1.56 Day range 1.81
1.56 52-week range 10.04
- YTD
- -82.23%
- 1 year
- -81.20%
News
seekingalpha.com Kyntra Bio, Inc. (KYNB) Q3 2026 Earnings Call Transcript Kyntra Bio, Inc. ( KYNB ) Q3 2026 Earnings Call November 16, 2026 5:00 PM EST Company Participants Thane Wettig - CEO & Director David DeLucia - Senior VP & CFO Carol Gaddum - Vice President of…benzinga.com Lake Street Maintains Buy on Kyntra Bio, Lowers Price Target to $8 Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release,…benzinga.com Oppenheimer Maintains Outperform on Kyntra Bio, Lowers Price Target to $30 Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.
benzinga.com HC Wainwright & Co. Maintains Buy on Kyntra Bio, Lowers Price Target to $18 HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.
zacks.com Kyntra Bio (KYNB) Reports Q3 Loss, Misses Revenue Estimates Kyntra Bio (KYNB) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of a loss of $3.66. This compares to a loss of $1.61 per share a year ago.benzinga.com Update: Kyntra Bio Q3 Adj. EPS $(3.42) Beats $(3.55) Estimate, Sales $1.762M Miss $1.766M Estimate Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.42) per share which beat the analyst consensus estimate of $(3.55) by 3.66 percent. This is a 5.23 percent decrease over losses of $(3.25)…
globenewswire.com Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining Initiation…
